InterPrivate Investment Partners V, Inc. filed its quarterly report on Form 10-Q with the SEC on November 9, 2026, covering the three and nine months ended September 30, 2026, its first full quarter following its initial public offering.
United States Commodity Index Funds Trust filed its Form 10-Q with the SEC on November 9, 2026, covering the quarterly period ended September 30, 2026, for its two series: United States Commodity Index Fund (NYSE Arca:USCI) and United States Copper Index Fund (NYSE Arca:CPER).
Plains GP Holdings, L.P. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting consolidated results for the three and nine months ended that date.
United States 12 Month Natural Gas Fund, LP (NYSE Arca:UNL) filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting a net asset value per share of $5.71 and total partners' capital of $15,985,679.
Berkshire Hathaway Inc. filed its Form 10-Q with the SEC on November 9, 2026, covering the quarterly period ended September 30, 2026, reporting consolidated financial results for the third quarter and first nine months of 2026.
Sohu.com Limited (NASDAQ:SOHU) reported unaudited financial results for the third quarter ended September 30, 2026, disclosing a 26% year-over-year decline in total revenues and a GAAP net loss attributable to the company of US$15 million.
FF EAI Robotics Ecosystem Inc. filed an 8-K on November 8, 2026, sharing a weekly business update from Founder and Global CEO YT Jia that highlighted OmniMind's top ranking on RoboColiseum's global leaderboard as of November 6, 2026.
Cars.com Inc. filed an 8-K on November 8, 2026, disclosing that its Compensation Committee granted 373,345 restricted stock units to Mausam Bhatt as an inducement to his employment as Chief Product Officer, effective November 2, 2026.
Johnson & Johnson (NYSE:JNJ) disclosed Phase 1 clinical results for the investigational combination of pasritamig and JNJ-9401 in metastatic castration-resistant prostate cancer, presented at the Society for Immunotherapy of Cancer 2026 Annual Meeting on November 8, 2026.
Johnson & Johnson issued a press release on November 7, 2026, announcing new patient experience findings from the Phase 2 DAHLIAS study of nipocalimab in Sjogren's disease, to be presented at the American College of Rheumatology Convergence 2026.